Found 15 matching trials
Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age PHASE1 This study will evaluate the safety and immunogenicity of a tetravalent den...
Show More Location
Center for Immunization Research, Johns Hopkins School of Public Health
Learn More & Join Trial
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 PHASE1 Infection with dengue viruses is the leading cause of hospitalization and d...
Show More Location
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Learn More & Join Trial
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge PHASE1 Zika virus (ZIKV) is an illness people can get from mosquitoes. The infecti...
Show More Location
Center for Immunization Research, Johns Hopkins School of Public Health
Learn More & Join Trial
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine PHASE1 Dengue viruses can cause dengue fever and other serious health conditions, ...
Show More Location
Center for Immunization Research, Johns Hopkins School of Public Health
Learn More & Join Trial
Dengue Controlled Human Infection Model in Dhaka, Bangladesh PHASE2 The primary objective is to determine, among dengue-naïve adults in an ende...
Show More Status
Active Not Recruiting
Learn More & Join Trial
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine PHASE1 Background:
Dengue is a disease caused by a virus transmitted by mosquitoe...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30 PHASE1 This study will evaluate the ability of a single dose of the live attenuate...
Show More Location
Center for Immunization Research, Johns Hopkins School of Public Health
Learn More & Join Trial
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart PHASE1 Dengue viruses can cause dengue fever and other more severe forms of diseas...
Show More Location
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
Learn More & Join Trial
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine PHASE1 Dengue viruses can cause dengue fever and other serious health conditions, ...
Show More Location
Center for Immunization Research, Johns Hopkins School of Public Health
Learn More & Join Trial
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh PHASE2 The purpose of this study is to evaluate the safety and immunogenicity of t...
Show More Location
International Centre for Diarrhoeal Disease Research, Bangladesh
Learn More & Join Trial